白杨甙 | 99-17-2

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 白杨甙
• 中文别名: 白楊苷
• 英文名称: Populin
• 英文别名: [(2R,3S,4S,5R,6S)-3,4,5-trihydroxy-6-[2-(hydroxymethyl)phenoxy]oxan-2-yl]methyl benzoate
• CAS: 99-17-2
• 化学式: C₂₀H₂₂O₈
• 分子量: 390.4
• InChiKey: HHSKNLJWHGXWPK-BFMVXSJESA-N

物化性质

• 熔点：
  180°C
• 沸点：
  435.61°C (rough estimate)
• 密度：
  1.2662 (rough estimate)
• LogP：
  2.050 (est)

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  28
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.35
• 拓扑面积：
  126
• 氢给体数：
  4
• 氢受体数：
  8

反应信息

• 作为产物：
  描述：

  [2-[(2S,3R,4S,5S,6R)-6-(benzoyloxymethyl)-3,4,5-trihydroxyoxan-2-yl]oxyphenyl]methyl 2-hydroxy-6-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxybenzoate 生成 白杨甙
  参考文献：
  名称：

  SHIMOMURA, HIROKO;SASHIDA, YUTAKA;YOSHINARI, KIYOSHI, PHYTOCHEMISTRY, 28,(1989) N, C. 1499-1502

  摘要：

  DOI：

文献信息

• Pharmaceutical composition for the treatment of diabetes mellitus
  申请人：——

  公开号：US20020197334A1

  公开（公告）日：2002-12-26

  This invention relates to a pharmaceutical composition containing herbal ingredients for the treatment of diabetes mellitus and more particularly, to the antidiabetic composition comprising 1) 15 herbal ingredients (i.e., Shinseng Radix, Coptis Rhizoma, Ligustri Fructus Semen, Salix spp. Cortex, Rhei coreani Rhizoma, Anemarrhena Rhizoma, Salviae Radix, Scrophulariae Radix, Lycii Cortex Radicis, Reynoutriae Radix, Platycodi Radix, Astragali Radix, Puerariae Radix, Atractylis Rhizoma, and Morus alba Radix Cortex), 2) vitamins such as B 1 and B 6 , and 3) zinc, manganese, chromium, germanium as inorganic materials. The antidiabetic herbal composition of this invention for the prevention and treatment of diabetes serves to lower the glucose level in diabetic patients and prevent the destruction of beta-cell in the pancreas, while increasing insulin secretion based on the mechanism of recovering the function of damaged beta-cell. Further, the antidiabetic herbal composition of this invention is quite effective in the treatment of insulin-dependent (type I) diabetes and non-insulin-dependent (type II) diabetes, since it shows the constant therapeutic effect due to better stability of therapeutic effect among individual patients.

  本发明涉及一种含有草药成分的制药组合物，用于治疗糖尿病，更具体地说，是包括以下成分的降糖组合物：1）15种草药成分（即人参、黄连、女贞子、柳树皮、大黄、知母、丹参、玄参、枸杞子、地锦草、桔梗、黄芪、葛根、苍术和桑白皮），2）维生素B1和B6，以及3）锌、锰、铬、锗等无机材料。本发明的降糖草药组合物可降低糖尿病患者的血糖水平，预防胰腺β细胞的破坏，同时通过恢复受损β细胞的功能来增加胰岛素分泌。此外，本发明的降糖草药组合物对治疗胰岛素依赖型（I型）糖尿病和非胰岛素依赖型（II型）糖尿病非常有效，因为它在个体患者中具有更好的治疗效果稳定性。
• Verfahren zur Herstellung eines Mittels zur Prophylaxe und/oder Bekämpfung zumindest eines Pflanzenschädlings
  申请人：Zorn, Andrea

  公开号：EP1287742A1

  公开（公告）日：2003-03-05

  Die Erfindung betrifft ein Verfahren zur Herstellung eines Mittels zur Prophylaxe und/oder Bekämpfung von zumindest einem Pflanzenschädling durch Zusammengeben mehrerer Komponenten. Das Mittel aus den Komponenten, jeweils in Gew.-%, 2 % bis 15 % der Blätter einer Thuja occidentalis (Cupressaceae) und 0,1 % bis 10 % der Rinde einer Populus tremuloides (Salicaceae), wird unter Zugabe eines Lösungsmittels, wobei dieses den Rest auf 100 Gew.-% bildet, hergestellt.

  本发明涉及一种通过组合几种成分来制备预防和/或控制至少一种植物害虫的制剂的工艺。该制剂由以下组分制备而成，每种组分的重量百分比为：2%至 15%的冲天香树叶和 0.1%至 10%的杨树树皮，并加入一种溶剂，后者构成剩余部分的重量百分比为 100%。
• Hydrosoluble [6)-O-alpha-d-glcp-(1->]n-6-o-bêta-d-glcp-(1->-phenllic derivatives with dermocosmetic, nutritional and therapeutic applications, and compositions containing said water soluble compounds
  申请人：Libragen

  公开号：EP2202237A1

  公开（公告）日：2010-06-30

  The invention relates to [6)-O-α-D-Glcp-(1→]n-6-O-β-D-Glcp-(1→-phenolic derivatives. These [6)-O-α-D-Glcp-(1→]n-6-O-β-D-Glcp-(1→phenolic derivatives of selected phenolics are new, have a solubility in water higher than that of their parent O-β-D-Glcp-(1→-phenolic derivatives and have useful applications in cosmetic, nutrition and pharmaceutical compositions, such as treating or preventing oxidative stress, a cancer, a cardiovascular disease, a bacterial infection, a viral infection, a fungal infection, a UV-induced erythema, an allergy, a metabolism disorder, diabetes, an obesity, an hormonal disorder, a bone disease, a pain, a brain disease, a mouth or teeth disease, an inflammatory or immune disorder.

  本发明涉及[6)-O-α-D-谷氨酰-(1→]n-6-O-β-D-谷氨酰-(1→酚类衍生物。这些[6)-O-α-D-Glcp-(1→]n-6-O-β-D-Glcp-(1→酚类衍生物是新的，在水中的溶解度高于其母体 O-β-D-Glcp-(1→酚类衍生物的溶解度，在化妆品、营养品和药物组合物中具有有用的应用，如治疗或预防氧化应激、癌症、心血管疾病、细菌感染、病毒感染、真菌感染、紫外线引起的红斑、过敏、代谢紊乱、糖尿病、肥胖症、荷尔蒙紊乱、骨病、疼痛、脑部疾病、口腔或牙齿疾病、炎症或免疫紊乱。
• WATER-SOLUBLE ADDITIVE COMPOSITION
  申请人：Sumitomo Bakelite Co.Ltd.

  公开号：EP3950910A1

  公开（公告）日：2022-02-09

  There is provided a water-soluble additive composition including a cyclic carboxylic acid, the water-soluble additive composition satisfying at least one of the following Conditions 1 to 4: (Condition 1) component (A) the cyclic carboxylic acid, which is other than the following component (B1), and component (B1) one or more selected from the group consisting of gallic acid and an ester thereof are included; (Condition 2) the total content of Na+ and NH4+ is equal to or more than 100 ppm and equal to or less than 5000 ppm with respect to the cyclic carboxylic acid; (Condition 3) the total inorganic ion content (excluding hydrogen ions and hydroxyl group ions) is equal to or more than 300 ppm and equal to or less than 5000 ppm with respect to the cyclic carboxylic acid; and (Condition 4) component (A) the cyclic carboxylic acid, which is other than the following component (B2), and component (B2) an amino acid are included.

  提供了一种包括环状羧酸的水溶性添加剂组合物，该水溶性添加剂组合物满足以下条件 1 至 4 中的至少一个条件： (条件 1)组分(A)环状羧酸，它不是以下组分(B1)，组分(B1)包括从没食子酸及其酯组成的组中选出的一种或多种； (条件 2）就环羧酸而言，Na+ 和 NH4+ 的总含量等于或大于 100 ppm，等于或小于 5000 ppm； (条件 3) 就环羧酸而言，无机离子总含量（不包括氢离子和羟基离子）等于或大于 300 ppm，且等于或小于 5000 ppm；及 (条件 4) 包括组分(A)环羧酸（以下组分(B2)除外）和组分(B2)氨基酸。
• Method for treating schizophrenia
  申请人：St. Jude Children's Research Hospital, Inc.

  公开号：US10441601B2

  公开（公告）日：2019-10-15

  The invention is directed to a method for treating the 22q11 deletion syndrome (22q11 DS) and schizophrenia (SCZ) by replenishment of decreased levels of miR-338-3p in thalamic neurons.

  本发明涉及一种通过补充丘脑神经元中降低的 miR-338-3p 水平来治疗 22q11 缺失综合征（22q11 DS）和精神分裂症（SCZ）的方法。